Research guide 2 of 6

The FDA pathway: IND and IDE

Which application your study needs, what goes into it, and the milestones that follow.KLINiSOL · Last reviewed October 2026

Drugs and biologics: the IND (21 CFR Part 312)

  • Pre-IND meeting: optional but recommended, to discuss design and regulatory strategy before you submit. 21 CFR 312.82(a) provides for it for drugs treating life-threatening and severely debilitating illnesses; other sponsors use FDA’s formal meetings process.
  • Submission: protocol, investigator brochure where required, chemistry and manufacturing information, and nonclinical safety data.
  • Review: the IND goes into effect 30 days after FDA receives it, unless FDA imposes a clinical hold, or earlier if FDA says the study may begin (21 CFR 312.40(b)).
  • IND safety reports: serious and unexpected suspected adverse reactions go to FDA and all participating investigators within 15 calendar days of the sponsor determining that they qualify; unexpected fatal or life-threatening ones must also be reported to FDA within 7 calendar days of first receipt (21 CFR 312.32(c)).
  • Annual report: within 60 days of the anniversary of the IND going into effect (21 CFR 312.33).

Devices: the IDE (21 CFR Part 812)

Significant-risk device studies need an FDA-approved IDE. Non-significant-risk studies follow abbreviated requirements, with IRB approval.

An example timeline

  • Months 0 to 3: protocol development and pre-IND meeting.
  • Month 4: IND or IDE submission.
  • Month 5: FDA review period and IRB submission.
  • Month 6: first participant, if there is no clinical hold.

Every study differs; use this only as a starting point.

Common pitfalls

  • Insufficient nonclinical safety data for first-in-human studies.
  • Incomplete chemistry, manufacturing and controls (CMC) documentation.
  • Design gaps: endpoints, safety monitoring or statistical power.
  • Consent forms missing required elements.

Checklist

IND submission checklist

  • Pre-IND meeting considered
  • Form FDA 1571 cover sheet
  • Form FDA 1572 obtained from each investigator before they take part (21 CFR 312.53(c))
  • Financial disclosure information from each investigator (21 CFR Part 54)
  • Final protocol
  • Investigator brochure, where required
  • Chemistry, manufacturing and controls information
  • Pharmacology and toxicology information
  • Plans for IND safety reports (15 days, plus a 7-day report for unexpected fatal or life-threatening reactions) and the annual report (within 60 days of the anniversary)
  • No enrollment until the IND is in effect and the IRB has approved

Practice with KLINiLEARN

Test yourself on this topic

We support IND and IDE applications, FDA communications and ongoing compliance throughout the trial.

Need support for your study?

A confidential, 30-minute protocol review. No commitment.